logo-loader

Abzena's John Burt 'very pleased' to close Taiwanese biopharma Thiobridge deal

Published: 10:30 11 Jul 2017 EDT

John Burt, chief executive of Abzena plc (LON:ABZA) tells Proactive they've inked an agreement with a Taiwanese biopharmaceutical company worth up to £128mln to license out its ThioBridge technology.

ThioBridge is an antibody drug conjugate (ADC) linker, which in layman’s terms means it attaches antibodies and other proteins to drugs.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 35 minutes ago